Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
DATA GRAPHICS | Data Byte

CHMP recommends Sanofi’s Enjaymo, Agios’ Pyrukynd and ADC’s Zynlonta 

September’s opinions include seven new medicines and 11 label extensions

By Gunjan Ohri, Data Content Analyst 
September 16, 2022 11:58 PM UTC
Updated on Sep 19, 2022 at 6:52 PM UTC

EMA’s CHMP recommended seven new medicines and label extensions for 11 previously approved drugs at its September meeting, including positive opinions for Sanofi’s Enjaymo, Agios’ Pyrukynd and ADC’s Zynlonta.

The agency recommended Enjaymo sutimlimab from Sanofi (Euronext:SAN; NASDAQ:SNY) for cold agglutinin disease, a rare autoimmune hemolytic anemia. If approved, the C1 protein inhibitor would be the first treatment for cold agglutinin disease in Europe. FDA approved Enjaymo in February...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Adc Therapeutics S.A.

Agios Pharmaceuticals Inc.

Sanofi

Takeda Pharmaceutical Co. Ltd.

BCIQ Target Profiles

CD19